INTRODUCTION: The role of individual monocyte subsets in inflammatory cardiovascular diseases is insufficiently understood. Although the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) regulates important processes for inflammation such as MMP-release, its expression and regulation on monocyte subsets has not been characterized. MATERIALS AND METHODS: In this clinical study, blood was obtained from 80 patients with stable coronary artery disease (CAD), 49 with acute myocardial infarction (AMI) and 34 healthy controls. Monocytes were divided into 3 subsets: CD14(++)CD16(-) (low), CD14(++)CD16(+) (intermediate), CD14(+)CD16(++) (high) according to phenotypic markers analyzed by flow cytometry. Surface expression of EMMPRIN was evaluated and compared with CD36 and CD47 expression. RESULTS: In all patients, EMMPRIN expression was significantly different among monocyte subsets with the highest expression on "classical" CD14(++)CD16(-) monocytes. EMMPRIN was upregulated on all monocyte subsets in patients with AMI as compared to patients with stable CAD. Notably, neither CD47 nor CD36 revealed a significant difference in patients with AMI compared to patients with stable CAD. CONCLUSION: EMMPRIN could serve as a marker for classical monocytes, which is upregulated in patients with acute myocardial infarction.
INTRODUCTION: The role of individual monocyte subsets in inflammatory cardiovascular diseases is insufficiently understood. Although the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) regulates important processes for inflammation such as MMP-release, its expression and regulation on monocyte subsets has not been characterized. MATERIALS AND METHODS: In this clinical study, blood was obtained from 80 patients with stable coronary artery disease (CAD), 49 with acute myocardial infarction (AMI) and 34 healthy controls. Monocytes were divided into 3 subsets: CD14(++)CD16(-) (low), CD14(++)CD16(+) (intermediate), CD14(+)CD16(++) (high) according to phenotypic markers analyzed by flow cytometry. Surface expression of EMMPRIN was evaluated and compared with CD36 and CD47 expression. RESULTS: In all patients, EMMPRIN expression was significantly different among monocyte subsets with the highest expression on "classical" CD14(++)CD16(-) monocytes. EMMPRIN was upregulated on all monocyte subsets in patients with AMI as compared to patients with stable CAD. Notably, neither CD47 nor CD36 revealed a significant difference in patients with AMI compared to patients with stable CAD. CONCLUSION:EMMPRIN could serve as a marker for classical monocytes, which is upregulated in patients with acute myocardial infarction.
Authors: Irene Cuadrado; Borja Castejon; Ana M Martin; Marta Saura; Paula Reventun-Torralba; Jose Luis Zamorano; Carlos Zaragoza Journal: PLoS One Date: 2016-09-20 Impact factor: 3.240
Authors: Mu-Peng Li; Xiao-Lei Hu; Yong-Long Yang; Yan-Jiao Zhang; Ji-Peng Zhou; Li-Ming Peng; Jie Tang; Xiao-Ping Chen Journal: Int J Environ Res Public Health Date: 2017-02-21 Impact factor: 3.390
Authors: Rafael Ramirez-Carracedo; Marcelo Sanmartin; Amadeo Ten; Ignacio Hernandez; Laura Tesoro; Javier Diez-Mata; Laura Botana; Karina Ovejero-Paredes; Marco Filice; Angel Alberich-Bayarri; Luis Martí-Bonmatí; Carlota Largo-Aramburu; Marta Saura; Jose Luis Zamorano; Carlos Zaragoza Journal: Circ Cardiovasc Imaging Date: 2022-06-09 Impact factor: 8.589
Authors: Ignacio Hernandez; Laura Tesoro; Rafael Ramirez-Carracedo; Javier Diez-Mata; Sandra Sanchez; Marta Saura; Jose Luis Zamorano; Carlos Zaragoza; Laura Botana Journal: Int J Mol Sci Date: 2021-03-12 Impact factor: 5.923